Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lm完成签到,获得积分10
1秒前
东方客警完成签到,获得积分10
2秒前
吴琼发布了新的文献求助10
2秒前
3秒前
illusion完成签到,获得积分10
3秒前
靖柔发布了新的文献求助20
4秒前
乐乐应助红豆采纳,获得10
4秒前
滴滴发布了新的文献求助10
4秒前
刘佳宇完成签到,获得积分10
4秒前
5秒前
希望天下0贩的0应助未何采纳,获得10
5秒前
jiao完成签到 ,获得积分10
6秒前
zhangfuchao发布了新的文献求助10
6秒前
6秒前
大模型应助某人的小镇采纳,获得10
6秒前
6秒前
小马甲应助美好的平露采纳,获得10
6秒前
所所应助hvgjgfjhgjh采纳,获得10
7秒前
8秒前
8秒前
zhaoxu完成签到,获得积分10
8秒前
9秒前
9秒前
1168163完成签到,获得积分10
9秒前
斯文冷梅完成签到,获得积分20
10秒前
鄙视注册完成签到,获得积分0
10秒前
刘腾发布了新的文献求助10
11秒前
搜集达人应助ssssssssssssssss采纳,获得10
11秒前
今后应助追寻思雁采纳,获得10
13秒前
瞿寒发布了新的文献求助10
13秒前
满意绝音发布了新的文献求助10
14秒前
踏实的土豆完成签到,获得积分10
15秒前
hys完成签到,获得积分10
15秒前
離殇完成签到,获得积分10
15秒前
无极微光应助BingyuDu采纳,获得20
15秒前
15秒前
楠333完成签到,获得积分10
16秒前
16秒前
大模型应助难度采纳,获得100
16秒前
bbx发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Cronologia da história de Macau 5000
Petrology and Plate Tectonics 800
Electrode Potentials 550
Association of Reentry Well-Being with Psychological Distress, Employment, and Housing Instability 15-Months After Incarceration 500
Trees of tropical Asia : an illustrated guide to diversity 500
Matrix Methods in Data Mining and Pattern Recognition 410
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7026995
求助须知:如何正确求助?哪些是违规求助? 8697511
关于积分的说明 18428718
捐赠科研通 6525822
什么是DOI,文献DOI怎么找? 3111110
关于科研通互助平台的介绍 2187996
邀请新用户注册赠送积分活动 2086780